The American Journal of Tropical Medicine and Hygiene
● American Society of Tropical Medicine and Hygiene
Preprints posted in the last 7 days, ranked by how well they match The American Journal of Tropical Medicine and Hygiene's content profile, based on 68 papers previously published here. The average preprint has a 0.06% match score for this journal, so anything above that is already an above-average fit.
Nelson, E.; Carcamo, P. M.; Ribeiro dos Santos, G.; Sylvestre Ribeiro, G.; Rodrigues da Costa, T.; Ilaria Dorigatti, I.; Salje, H.; Moreira, L. A.; Cummings, D. A. T.; Ko, A. I.
Show abstract
Wolbachia-based interventions were less effective in achieving introgression in Rio de Janeiro than other settings. Reduced introgression occurred in locations where dengue was historically high, raising concerns of inequity. We examined factors affecting Wolbachia introgression in Rio through trajectory modeling, spatiotemporal Bayesian models, and Ae. aegypti abundance estimation. During the intervention (2017-2020), Wolbachia introgression was 26% (median; IQR,14-44%), with four distinct trajectories. Despite receiving more releases, densely populated areas with low socioeconomic status had lower introgression. In spatiotemporally explicit multivariable regressions, higher Ae. aegypti abundance, temperature, population density and lower socioeconomic status were associated with reduced introgression. Improved characterization of Ae. aegypti abundance and other structural/environmental predictors of introgression could be used to calibrate release doses to ensure equitable benefits from Wolbachia interventions.
Ekat, M. H.; Amona, M.; Andzi Barre, M.; Bendett Lebaho, P.; Aloumba, G. A.; Adoua Doukaga, T.
Show abstract
Background: Severe malaria remains a major cause of hospitalization in malaria-endemic sub-Saharan Africa, and anemia is among its most frequent severity criteria. Data on the impact of anemia on hospital length of stay (LOS) among adults with severe malaria remain limited in Central Africa. We assessed the impact of anemia on LOS among adults hospitalized for severe malaria in Brazzaville, Republic of Congo. Methods: We conducted a cross-sectional, descriptive, and analytic study of medical records from adult patients ([≥]18 years) diagnosed with severe malaria (WHO criteria) and admitted to four hospitals in Brazzaville between January 2020 and December 2024. We dichotomized LOS as short (<5 days) or prolonged ([≥]5 days). Multivariable logistic regression, using a backward stepwise procedure, identified factors independently associated with prolonged LOS; isolated hemoglobinuria served as the reference severity category. Results: Among 523 patients hospitalized for severe malaria, 296 met the inclusion criteria. Median age was 25.5 years (IQR 20-40); 51.7% were female, and 82.1% had a low socioeconomic status. Median hemoglobin was 10.55 g/dL, and median LOS was 4 days (IQR 3-5). In multivariable analysis, prolonged LOS was independently associated with delay to consultation (aOR 1.25/day, 95% CI 1.09-1.44), isolated anemia (aOR 7.07, 1.23-40.55), convulsions (aOR 5.86, 1.81-18.97), prostration (aOR 4.42, 1.21-16.2), and impaired consciousness (aOR 4.29, 1.17-15.7). The strongest associations involved combined severity criteria: anemia with prostration (aOR 8.58), anemia with jaundice or hemoglobinuria (aOR 16.21), and impaired consciousness with anemia (aOR 33.31). Conclusions: Anemia is a major, potentially modifiable determinant of prolonged hospitalization in adults with severe malaria, with a markedly amplified effect when combined with neurologic impairment. Early anemia screening, improved access to safe blood transfusion, and reduced delays to care could shorten hospital stays and ease the burden on health systems in this setting.
Omar, A.; Marangu-Boore, D.; Bukachi, F.; Were, F.
Show abstract
Type 1 diabetes mellitus (T1DM) remains a growing global health priority, with disproportionate underdiagnosis, delayed diagnosis, and mortality in sub-Saharan Africa. Despite the introduction of the Life for a Child (LFaC) programme in Kenya, which provides free insulin, glucose-monitoring supplies, and specialist education, no published studies have examined the determinants of glycaemic control among Kenyan children and adolescents with T1DM. This study aimed to determine the proportion of children and adolescents achieving good glycaemic control and to identify the socio-demographic and clinical determinants of glycaemic control at a tertiary hospital in Kenya. This cross-sectional study enrolled 160 children and adolescents with T1DM attending the paediatric diabetes clinic at Kenyatta National Hospital, Nairobi, between September 2025 and May 2026. Sociodemographic and clinical data were collected through structured interviews and physical examination. Poor glycaemic control was defined as HbA1c >7.5%. Associations between candidate determinants and glycaemic control were assessed using chi-square or Fisher's exact tests. Variables with p<0.2 on bivariate analysis were entered into a multivariable logistic regression model; Firth's penalized-likelihood method was used given the small number of participants achieving good control. Only 9 participants (5.6%) achieved the target HbA1c of [≤]7.5% (mean HbA1c 11.02%, SD {+/-}2.29), and only 5 of 133 patients (3.8%) had [≥]70% of glucometer readings within the target blood glucose range (3.9-10.0 mmol/L).On bivariate analysis, household income (p=0.026) and self-monitored blood glucose (SMBG) frequency (p=0.018) were significantly associated with glycaemic control. In an exploratory multivariable regression analysis (Firth penalized logistic regression, given the small number of participants with good control), only SMBG frequency [≥]4 tests/day remained independently associated with lower odds of poor control (adjusted OR 0.19, 95% CI 0.04-0.84, p=0.028); the effect of household income was attenuated after adjustment. Glycaemic control remains markedly poor among children and adolescents with T1DM in this Kenyan tertiary hospital setting despite structured programmatic support. Frequency of self-monitoring, rather than household income alone, was the factor most strongly associated with glycaemic control, suggesting that strengthening access to glucose-testing supplies and supporting their consistent use should be prioritised in care, alongside attention to socioeconomic barriers. Longitudinal studies are needed to confirm these associations.
Simons, D.
Show abstract
Background. Nigeria's reported Lassa fever case fatality ratio (CFR) rose from 18.9% at week 23 of 2025 to 25.0% in 2026, prompting concerns over failing clinical care. Because surveillance artefacts can also alter CFRs, candidate mechanisms that published data can resolve were identified and evaluated. Methods. This ecological study extracted weekly state-level counts from 474 Nigeria Centre for Disease Control and Prevention situation reports (2017-2026). Per a pre-specified plan, years were compared at phase-matched points, year-on-year CFR changes were decomposed into within-state and between-state components, and tipping-point ascertainment shifts calculated. Weekly incident and cumulative published totals were compared post hoc. Findings. Of 11 candidate mechanisms, 2 could be evaluated fully and 5 in part. On weekly incident counts, 2026 did not differ from 2025 at the phase-matched midpoint (+0.3 percentage points, 95% CI -5.0 to 7.6); within-state (-1.1, 95% CI -4.7 to 3.0) and between-state (+0.5, -2.0 to 2.9) components spanned zero. Conversely, the published cumulative CFR was 5.4 to 6.2 percentage points higher because 70 deaths were added retrospectively by week 36 outside weekly reports. Reconciling cumulative figures would require 279 missed survivors (6% of suspected cases not confirmed). Interpretation. The 2026 CFR rise came from deaths added to cumulative totals outside the weekly counts, and published data cannot attribute it to care. Endemic zoonotic CFRs cannot serve as clinical outcome measures unless testing volumes, deaths added late, and post-mortem sampling are published alongside case counts. Funding. US NSF-NIH-NIFA EEID; UK BBSRC; Birgitta Sintring Fellowship (Uppsala University).
Fletcher, C.; Mila, C.; Moirano, G.; Araujo, E.; Lührsen, D.; Codeco, C.; Codeco Coelho, F.; Lowe, R.
Show abstract
Brazil has one of the highest dengue burdens globally, with transmission influenced by climate events. Yet, the effects of compound climate extremes on dengue risk and prediction have not been quantified to date. Using a Bayesian spatiotemporal model of monthly dengue cases across 435 health regions from 2010 to 2025, we estimated relative risk associated with interacting long-lag and short-lag drought indicators and temperature anomalies across nine Koppen-Geiger climatic zones, adjusting for absolute temperature and El Nino-Southern Oscillation. Long-lag dry, mid-lag warm and short-lag wet conditions were associated with the highest relative risk in five climatic zones, with temperature anomalies modifying hydrometeorological dynamics more strongly in temperate than tropical areas. Climate covariates improved the prediction of case counts and outbreaks compared to baseline models at lead times of 1, 3, 6 and 12 months, and for the upcoming season 5 months ahead. Improvements were greatest in the Northeast, Southeast, and Midwest. Recent dengue incidence provided the greatest improvement at the 1-month lead, whereas combining incidence with climate information performed best at 3- and 6-month leads. We extended our framework to weekly state-level predictions of the season ahead to align with national public health planning. We proposed a multi-staged dengue forecasting approach to enhance early warning and response across Brazil.
Hussain, A.; Bhowmick, S.; Mateus-Pinilla, N.; Smith, R. L.
Show abstract
Tick-borne disease risk reflects the combined influence of vector abundance, pathogen prevalence, human exposure, and seasonal activity, yet these components are rarely integrated at the county level. We developed species-specific ecological risk scores for three medically important tick species (Acari: Ixodidae): Amblyomma americanum (L.), Dermacentor variabilis (Say), and Ixodes scapularis Say, across all 102 Illinois counties using data from 2019 to 2022. County-level predicted tick abundance and pathogen prevalence were scaled and combined using equal weights to generate primary vector-level risk scores. Robustness to the equal-weight assumption was evaluated by systematically varying the relative weights assigned to abundance and pathogen prevalence, while a separate sensitivity analysis incorporated reported tick-bite incidence where available. Associations with human disease were evaluated using negative binomial regression of tick-borne disease case counts on the corresponding risk scores, with county population included as an offset. Monthly phenology indicators were constructed by integrating human disease cases, reported tick bites, and sampled tick abundance and were evaluated in relation to temperature and precipitation. Seasonal risk was estimated by combining county-level vector risk with species-specific monthly phenology, generating monthly risk surfaces that were deployed through an interactive R Shiny application. Higher risk scores were significantly associated with greater disease case rates for each tick species. County rankings were highly stable under moderate changes in abundance and prevalence weighting. Seasonal activity differed among species, with A. americanum and D. variabilis showing concentrated warm-season risk and I. scapularis exhibiting a broader seasonal profile. These county-level seasonal risk maps identify where and when relative tick-borne disease risk is elevated in Illinois, supporting targeted prevention, surveillance, and clinical awareness.
van Wyk, S.; Gwasupika, J.; Mapahla, L.; Asua, V.; Harrison, L. E.; Kamya, M. R.; Nankabirwa, J. I.; Barnes, K. I.
Show abstract
Artemisinin partial resistance (ART R) associated Plasmodium falciparum Kelch13 mutations is expanding across Africa. However, their population level consequences remain poorly understood, particularly in settings of moderate to high malaria transmission. We investigated associations between Kelch13 and partner drug mutation prevalence and monthly confirmed malaria incidence across 16 Ugandan districts from 2017 to 2022, using integrated molecular, epidemiological, climatic, malaria control, and antimalarial resistance data and negative binomial regression. Combined prevalence of WHO validated and candidate Kelch13 mutations increased over the study period. Each 10 percentage point increase in Kelch13 prevalence was associated with a 13.1% higher incidence after multivariable adjustment (aIRR 1.131, 95% CI 1.090 to 1.174). Furthermore, each 10% increase in pfcrt K76T was associated with a 24% increase in malaria transmission. As expected, ITN distribution >80%, IRS coverage >90%, and higher altitude were associated with lower incidence, whereas temperatures of 25 to 30C, relative humidity of 60 to 80%, and higher precipitation were associated with higher incidence. The persistence of the Kelch13 and pfcrt K76T association after adjustment suggests that expanding ART R associated parasite populations are independently associated with malaria incidence. The relationship may be bidirectional. These findings support interpreting ART R within its ecological and intervention context and integrating molecular, epidemiological, and malaria control surveillance to safeguard antimalarial efficacy.
Couper, L. I.; Camponuri, S. K.; Sykes, J. E.; Li, X.; Hubbard, A. E.; Bustamante, B. L. M.; Williamson, T.; Ruberto, I.; Sondermeyer-Cooksey, G.; Karmarkar, E. N.; Yu, A. T.; Heaney, A. K.; Head, J. R.; Remais, J. V.
Show abstract
Importance: Coccidioidomycosis, also known as Valley fever, is a serious fungal disease caused by inhaling Coccidioides spores aerosolized from the soil. Despite rising public health concern, the distribution and incidence of coccidioidomycosis in the US remain poorly characterized as not all states are required to report cases, and case under-ascertainment is presumed to be high, particularly outside of the endemic region. Objective: To estimate monthly, county-level coccidioidomycosis incidence across the US while accounting for widespread under-ascertainment. Design, Setting, and Participants: We integrated multisource data, including human cases diagnosed in electronic health records, serological testing of dogs, and ecological and sociodemographic predictors, in a machine learning model estimating monthly, county-level coccidioidomycosis incidence. The model was trained on surveillance data from Arizona and California from 2013 to 2023, then applied to predict incidence in states across the contiguous US over the same time period. Main Outcomes and Measures: Incidence of coccidioidomycosis at the monthly county level. Results: The model predicted coccidioidomycosis incidence from 2013 to 2023 for 3,108 counties from all states in the contiguous US. The model identified 60 counties in non-reporting states where predicted incidence was [≥]2 cases per 100,000 population (considered moderate to high incidence). In states with mandatory reporting outside of Arizona and California, the model predicted county-level incidence rates that were 28% higher (95% bootstrap interval, 0.1%-69.8%) than those captured in national surveillance, equating to a total of 608 potentially missed cases per year (95% bootstrap interval, 340-964). Conclusions and Relevance: In this cross-sectional study, the model quantified case under-ascertainment for coccidioidomycosis relative to Arizona and California, and highlighted the potential for alternative data sources to fill in gaps in mandatory reporting. Estimating incidence while accounting for under-ascertainment and non-reporting may help efforts to improve public and physician awareness and to detect emergence in new regions.
Tsalah, J. M.; Bobskill, V.; Ravenhurst, J.; Ross, K.; Gardner, A.; Landesman, W.; Lover, A. A.
Show abstract
Vegetation plays a critical role in shaping fine-scale tick density by structuring local microclimates, habitat resources, and host interactions that largely determine tick survival and activity, with implications for tick-borne disease transmission. Tick burden in the United States continues to increase, with annual reported tick-borne disease cases more than doubling from 2004 through 2019. These trends call for a broader scope of tick-mitigation strategies that go beyond traditional prevention measures that focus on personal protection; and there is an opportunity to inform habitat-level interventions. Here, we quantify fine-scale vegetation structure across 48 subplots at tick surveillance sites in Western Massachusetts to assess local habitat features associated with Ixodes scapularis density and potential for human-tick contact risk. In assessing understory and overstory vegetation attributes, this study identified life stage-specific differences in predicted tick density, with higher adult densities in areas with deeper leaf litter and presence of invasive plant species and nymphs associated with high presence of ferns. Both adult and nymphal Ix. scapularis were predicted at higher densities in relatively low basal area forests (18.9 to 26.9 m2/hectare). This study design provides a simple, low-cost framework for organizations looking to incorporate tick-informed forest measurement ecology into their public health tick surveillance protocols with minimal training.
McGregor, A.; Suggala, S.; Abdeljaber, W.; Michael, J.; Shoemake, B.
Show abstract
Since its inception in 2003, the United States President's Emergency Plan for AIDS Relief (PEPFAR) has played a central role in HIV/AIDS prevention and treatment across Sub-Saharan Africa. Following the January 2025 suspension of United States foreign aid, which includes PEPFAR funding, countries across Sub-Saharan Africa demonstrated varying governmental responses to the resulting HIV funding disruptions. This study evaluates whether national characteristics were associated with a country's ability to respond to this funding crisis. Countries in Sub-Saharan Africa receiving PEPFAR funding were classified into one of three response categories: Level 1 (minimal or no governmental response), Level 2 (government response without sufficient plans or resources to fully offset funding losses), or Level 3 (high governmental response with strategies to maintain HIV/AIDS prevention and treatment services). Response categories were compared with national Human Development Index (HDI), GDP per capita, HIV prevalence, total population living with HIV, annual HIV mortality, and historical PEPFAR funding. Univariable proportional-odds ordinal logistic regression was used to identify factors associated with response level. Five countries (17.2%) were classified as Level 1, 10 (34.5%) as Level 2, and 14 (48.3%) as Level 3. Higher HDI was significantly associated with stronger governmental response (OR = 4.05; 95% CI, 1.49-11.04; Holm-adjusted p = 0.0376). GDP per capita (OR = 2.35; 95% CI, 1.00-5.51; unadjusted p = 0.0489) and HIV prevalence (OR = 3.53; 95% CI, 1.03-12.11; unadjusted p = 0.0452) demonstrated positive associations before adjustment for multiple comparisons, but neither remained significant after Holm correction (adjusted p = 0.2261 for both). Historical PEPFAR funding, total population living with HIV, and annual HIV mortality were not significantly associated with response level after adjustment. Countries with higher levels of human development demonstrated stronger governmental responses to the 2025 PEPFAR funding disruptions. Several countries with minimal documented responses were also affected by active conflict or political instability, potentially compounding their vulnerability to treatment interruptions. These findings suggest that broader national development may play an important role in governmental responses to funding disruptions and highlight the need to strengthen resilient health systems, diversify HIV financing, and prioritize support for countries at greatest risk of future funding shocks.
Ogwel, B.; Onyando, B. O.; Nyawanda, B. O.; Awuor, A. O.; Ogutu, J.; Ochieng, J. B.; Garcia Quesada, M.; Pavlinac, P. B.; Lau, M.; Omore, R.; Rogawski McQuade, E. T.
Show abstract
Introduction Despite the significant burden of Shigellosis, routine surveillance systems in resource-limited settings lack predictive capabilities to guide proactive public health responses. Consequently, we developed and evaluated the accuracy, uncertainty and computational cost of multi-horizon forecasting models for Shigella incidence among children <5 years in rural western Kenya using 16-year longitudinal incidence time-series. Methods We estimated monthly Shigella incidence using data from three pediatric enteric studies (2008-2024), supplemented with Kenya Health Information System during inter-study gaps. Incidence estimates incorporated sampling, healthcare-seeking, stool-testing, and pathogen-specific weights, with bootstrap-derived 95% confidence intervals. Predictors included Google Trends health-related indicators, climate, temporal trends, and seasonality. Forecasts at 1-, 3-, and 6-month horizons were evaluated using rolling-origin validation. Following horizon-specific predictor selection using Boruta, 14 state-space, machine-learning, and hybrid models were compared using point-forecast and probabilistic metrics, bootstrap confidence intervals, and Model Confidence Sets. Adaptive conformal prediction recalibrated prediction intervals, while Shapley Additive exPlanations assessed predictor contributions. Results Mean monthly Shigella incidence was 2.51 per 100 child-years (standard deviation=1.85). Shigella dynamics in Kenya can be forecast beyond seasonal persistence alone for up to six months reducing absolute errors by ~ 33%. However, optimal model architectures and predictor sets shift systematically across forecasting horizons. Temporal trend and recent incidence were the dominant predictors, while predictor importance shifted with forecast horizon toward syndromic, pharmaceutical, seasonal, and lagged environmental signals. Extreme Gradient Boosting performed best at 1 month (Root mean squared error [RMSE]=1.86), remained competitive at 3 months (RMSE=1.89), whereas exponential smoothing (ETS) performed best at 6 months (RMSE=2.05). Forecast accuracy declined with increasing horizon. ETS and TBATS provided the best-calibrated prediction intervals, whereas machine-learning models generally under-covered. Model Confidence Sets demonstrated horizon-dependent model distinguishability. Conclusion Horizon-specific model selection balancing predictive accuracy, uncertainty calibration, and computational feasibility could strengthen operational early warning systems for shigellosis.
Hounsell, R.; Silal, S. P.; Norman, J.; Monyake, R.; Immaculate, A.; Besigye, A.; Biroma, G.; Magoola, J.; Kishore, N.; Pallas, S. E.; Ward, K.
Show abstract
Routine infant vaccination has helped reduce cases and deaths from diphtheria, tetanus, and pertussis globally. However, these diseases continue to pose serious health risks as protective immunity wanes over time. Three booster doses of diphtheria-tetanus-pertussis-containing vaccine (DTPCV) administered from 12-months to 15-years of age increase duration of protection beyond childhood. Growing demands on government health spending underscore the importance of understanding the health and economic impact of vaccines prior to introduction. Using an integrated multi-disease epidemiological-economic model, we estimated the health impact (cases averted, deaths averted, and changes to population immunity) and budget impact of introducing DTPCV booster doses in Uganda. Compared to no DTPCV boosters, introducing all three booster doses is projected to result in 2.2 times the proportion of the population protected against symptomatic diphtheria and 2.8 times against tetanus infection among Ugandans under 15 years of age by 2039. Compared to introduction of the early childhood booster (EC) at 18 months of age, introducing all three DTPCV boosters simultaneously is projected to avert 3.2 times the number of tetanus cases over fifteen years at 2.4 times the incremental cost. The projected government vaccination cost per planned dose was USD 0.58 for simultaneous introduction of all three boosters compared with USD 0.68 for the EC booster alone. The average annual incremental cost of all three DTPCV booster doses is USD 2.79 million. Under modelled assumptions, simultaneous introduction of all three DTPCV booster doses in Uganda provides the greatest health gains, with a lower government vaccination cost per planned dose than introduction of the EC booster alone, but may still pose affordability challenges for Ugandas government.
Cunha, J.; Addisu, A.; Matano, D.; Younis, B.; Bayiyana, A.; Kumar, R.; Tiwari, R.; Engel, J.; Hogg, K.; Wiggins, R.; Biwott, W.; Osuna, F.; Ichugu, C.; Zeleke, A. J.; Ayele, E.; Sande, O. J.; Khalil, E. A. G.; Ibrahim, H. M. H.; Mahmoud, M. A.; Zakaria, A. I. B.; Adiko, B.; The Immstat@Cure Consortium, ; O'Toole, P.; D'Alessio, F.; Lacey, C. J. N.; Engwerda, C. R.; Sundar, S.; Mbui, J.; Hailu, A.; Mbuchi, M.; Musa, A.; Olobo, J.; Kaye, P. M.
Show abstract
Background: Visceral leishmaniasis (VL) is the most severe form of leishmaniasis and is caused by parasites from the Leishmania donovani complex. VL is endemic in 54 countries, with East Africa (EA) accounting for [~]70% of the global burden. Therefore, there is a pressing need to prioritize VL research in EA. Transcriptomics analysis in rodent models and patients following treatment have shown that immune homeostasis is not restored by the end of treatment. However, comprehensive proteomic studies in VL remain scarce, and the few available studies were conducted outside EA. Methodology/Principal Findings: As a part of ImmStat@cure consortium, we used the Olink Reveal proximity extension assay to profile circulating proteins in VL patients from Ethiopia, Kenya and Sudan. By comparing patients at admission and 17 days after treatment with SSG-PM, we have identified a systemic Th1-cytotoxic inflammatory profile at admission, characterized by high abundance of IFN{gamma}, IL-1B, IL-6, and the granzymes A and B. Chemokines with high abundance included CXCL8/10/11, CCL3, CCL4, CCL8, CXCL8 and CCL20, consistent with the recruitment of monocytes, macrophages, T cells, and NK cells. There were also evidence of immune regulation/exhaustion, with high levels of PD1, PD-L2, IDO1 and KYNU. Although the immune profiles were similar at admission, country specific differences were observed after treatment. Kenyan patients exhibited a sustained inflammatory profile and signatures of myeloid recruitment, characterized by high levels of IL-1B, IL-6 , IL-12A, CXCL8, CCL2, CCL3, CCL4, CCL7 and CEBPB. Sudanese patients showed signatures associated with lymphocyte activation and immune regulation. Conclusions/Significance: These results highlight the complexity of the immune changes associated with VL, identifying both core conserved profiles at admission and country-specific profiles after treatment. The data provided here will provide a valuable resource for future comparative studies across more diverse different geographic regions, for linkage studies that assess the impact of parasite genotype on immune / metabolic response and for use during the evaluation of new therapies against VL.
da Silva, G.; Tapaopong, P.; Holzschuh, A.; Sattabongkot, J.; Nguitragool, W.; Koepfli, C.
Show abstract
Population genomic studies have revealed strong regional structure in Plasmodium knowlesi across Southeast Asia. To facilitate routine genomic surveillance, we developed a targeted amplicon sequencing panel that preserves the large- and small-scale population genetic structure. We screened published genomes for short, highly polymorphic targets and a 30-SNP barcode. We validated multiplexed amplification and sequencing using a portable Oxford Nanopore Technologies MinION sequencer on 28 clinical infections from four southern Thai provinces collected between 2018-2023. Twenty-seven loci yielded sequence data and 23 infections with data from at least eight loci were retained for analysis. Across the 23 Thai infections and 104 published Malaysian genomes, 586 diverse SNPs were observed. The amplicon panel and 30-SNP barcode retained the major population structure observed in genome-wide data, including a clear distinction between Bornean and Peninsular Malaysian infections and two clusters in Borneo. Across newly sequenced Thai infections, 25 loci were diverse and showed substantial diversity (mean expected heterozygosity = 0.69). All infections were effectively monoclonal. Pairwise identity-by-descent revealed substantial recent relatedness, with 46 of 253 pairs at or above 0.5. Two Thai genetic groups (n = 12 and n = 11) were observed, mirroring previously observed structure in peninsular Malaysia. Groups were not significantly associated with province or collection year. In conclusion, targeted sequencing can reveal geographically informative population structure across scales and thus support surveillance.
Lambert, B. L.
Show abstract
Background. Regulatory pressure to avoid confusingly similar drug names appears to have pushed manufacturers to coin more distinctive proprietary names, but no one has quantitatively analyzed this trend. Objective. To determine whether proprietary drug names became more orthographically distinctive (unusual in spelling) over time. Methods. We examined 1,321 US Food and Drug Administration (FDA) new molecular entity (NME) names (1985-2024), 2,769 FDA Orange Book trade names (1982-2026), 177,337 US pharmaceutical trademarks (1980-2026), and 1,273 generic names (1982-2025). Compared to prior names (including those already marketed) and ordinary English, we scored each name's character trigram (three-letter sequence) surprisal (statistical unexpectedness) and its edit-distance similarity to the closest existing names. Linear regression tested time trends, controlling for name length. Results. Mean NME trigram surprisal rose in every decade between the 1980s and 2020s, from 7.21 to 8.50 nats (natural-logarithm units, higher meaning less predictable), an 18% increase (b = 0.038, p < .001, R2 = 0.34). Half of 2020s names (7% in the 1980s) contained a letter sequence found in no common English word (e.g., Jesduvroq, Omvoh). Nearest-neighbor similarity fell after the early 1990s. Trademark data showed the same trend (b = 0.016, p < .001). Generic names showed a weaker trend (b = 0.011, R2 = 0.063). Conclusions. Over four decades, drug names became more orthographically distinctive, consistent with namespace crowding, deliberate efforts to avoid confusing names, and branding strategy. Because unfamiliar letter sequences can introduce other error pathways, increased distinctiveness does not necessarily imply improved safety.
Dali, A. M.; Vujicic, A.; Gato, D.; Volkan, E.
Show abstract
Abstract Background: Cyprus has transitioned into a high-alert zone for mosquito-borne viruses. This necessitates a proactive assessment of its future physicians. Following the 2022 re-establishment of Aedes aegypti in Larnaca and Aedes albopictus in Limassol, Cyprus, the island is now biologically primed for local outbreaks of dengue, Zika, and chikungunya, alongside Culex-borne West Nile virus. The study assessed medical students' knowledge and risk perception. Methods: A cross-sectional online survey administered the validated MosquitoWise Health Belief Model instrument to undergraduate-entry and graduate-entry students at a university in Cyprus in mid-2026. Results: Of 1023 students, 119 responded (11.6%), with pre-clinical students overrepresented (p<0.001). Mean knowledge was 5.43/9, stronger on mosquito biology (72.5%) than virus knowledge (54.2%). Median severity was 6.00/7 against susceptibility 4.25/7. Knowledge differed by study stage (p<0.001), correlated with severity (rs = 0.399) but not susceptibility. Conclusions: The study establishes a critical baseline for pre-clinical medical students in Cyprus. Overall, participants performed better on mosquito biology when compared to mosquito-borne viruses and how they spread. Our findings highlight the value of integrating theoretical microbiology with clinical practice in medical education to enhance physicians' preparedness for the changing landscape of newly emerging infections in Cyprus and across Europe as a whole. Key Words: Arboviruses, Cross-Sectional Studies, Cyprus, Health Belief Model, Medical Students, Risk Perception.
Wallace, H. L.; Halbrook, M. L.; Kompany, J. P.; Hoff, N. A.; Merritt, S.; Mukadi, P.; Beya, M.; Kalengi, H.; Tambu, M.; Mossoko, Z.; Kelly, J. D.; Ball, A. H.; To, A.; Wong, T.; Kavunga-Membo, H.; Hensley, L. E.; Lehrer, A. T.; Kindrachuk, J.; Mbala-Kingebeni, P.; Rimoin, A. W.
Show abstract
Background: Filoviruses, specifically Ebola virus (EBOV), Bundibugyo virus (BDBV), and Marburg virus (MARV), have been the etiologic agents of multiple outbreaks of severe disease in the Democratic Republic of the Congo (DRC). Two EBOV-specific vaccine regimens have been approved for use in outbreak scenarios, including the Ad26.ZEBOV/MVA-BN-Filo (Zabdeno/Mvabea) two-dose vaccine, where the MVA-BN-Filo booster dose contains EBOV, MARV, and Sudan (SUDV) virus glycoproteins (GPs) and the nucleoprotein from Tai Forest virus. While long-term immunogenicity of up to two years has been found in clinical trial settings, limited real-world data exists. Methods: Using a multiplexed immunoassay, samples (n=698 at baseline) collected in Mbandaka, Equateur province, DRC, between September 2023 and October 2024 were assessed for seroreactivity to six filovirus antigens (1 BDBV, 2 EBOV, 2 MARV, and 1 SUDV) at three distinct periods: baseline/pre-vaccination, 6-8 weeks post-first dose (Zabdeno), at booster administration (Mvabea), and one-year post-boost dose. Results: Substantial filovirus seroreactivity was found at baseline, with 48.7% (n=340/698) of individuals being seroreactive to at least one virus antigen. High baseline seroreactivity was found against BDBV GP (31.1%, n=217/698), with lower baseline seroreactivity to EBOV GP (15.5%, n=106/698), comparatively. Overall EBOV GP seroreactivity increased to 66.8% (n=376/563) at one year-post vaccine boost and 57.6% (n=250/434) of participants were seroreactive. Despite the booster dose inclusion of SUDV GP and MARV GP, there were no substantial increases in reactivity against either antigen at subsequent timepoints. Overall filovirus seroreactivity increased at all timepoints for the entire cohort, although filovirus reactivity decreased over the study period for those who were seroreactive at baseline. Findings: These data highlight detection of significantly elevated seoreactivity to EBOV GP following first-dose administration of Ad26.ZEBOV, which remained relatively stable one-year post-booster dose administration. Additionally, this study identifies high levels of baseline seroreactivity to BDBV GP despite no previous documented outbreaks in this region of DRC. These data suggest that vaccination with the Ad26.ZEBOV-MVA-BN-Filo vaccine induces stable seroreactivity against EBOV GP, but not to other filovirus antigens.
Merritt, S.; Kindrachuk, J.; Nkamba, D.; Hoff, N. A.; Kalengi, H.; Halbrook, M.; Kamba, L.; Beya, M.; Petrichko, S.; Wallace, H. L.; Luhata, C.; Kaba, D.; Rimoin, A. W.
Show abstract
We report general acceptance (79.0%) of Ebola vaccination in the Democratic Republic of the Congo (DRC) between 2023-2024 (n=5,062). Acceptance varied significantly by province with acceptance ranging from 47.6% in Kongo Central to 92.1% in Tshuapa province and was highest among healthcare workers. While Ebola vaccine acceptance and disease knowledge are relatively strong nationally in the DRC, regional differences do exist and may impact future vaccine rollout.
Agarwal, Z.; Mishra, S.; Kaur, J.; Sharma, R.; Sethi, T.
Show abstract
Background: Antimicrobial resistance (AMR) is a growing global health threat, and India's high antibiotic consumption makes public knowledge, attitudes, and practices (KAP) a critical determinant of stewardship outcomes. Existing Indian KAP evidence is drawn from small, localised cohorts, leaving a gap in nationwide, digitally-sourced data. This study aimed to describe antibiotic-related knowledge, attitudes and self-reported practices among users of a digital healthcare platform in India, examine demographic and regional variation, and identify potential areas for future stewardship interventions. Methods: A cross-sectional survey was conducted among adult users of the Tata 1mg platform (December 2025-February 2026), with participants invited via an in-app banner. Knowledge and attitude were each scored on a 0-4 scale (4 items); practice was scored as a percentage of applicable items answered favourably, with scoring adjusted for branching logic based on antibiotic-access route. Of 10,726 respondents who started the survey, 4,883 completed it (45.5%). City of residence was mapped to one of six regions (India's five statutory Zonal Council zones plus a North-Eastern region) for 4,187 respondents. Associations with demographic characteristics were assessed using multivariable linear regression, and regional differences were assessed using one-way ANOVA. A parallel survey of 256 physicians was conducted to enable patient-provider comparison. Results: Mean scores were: knowledge 2.28 (SD 1.19), attitude 0.91 (SD 1.14), practice 44.9% (SD 33.4); attitude, not knowledge, was the weakest domain. Older age was associated with higher scores across all domains (practice: B=12.52, p<0.001 for age [≥]65 vs. 18-34); city tier was independently associated with lower knowledge and attitude (Tier 3 vs. Tier 1: p=0.010 and p<0.001, respectively). Regional differences were non-significant for knowledge and practice but significant for attitude (F=2.56, p=0.026, ^2=0.003), driven by lower scores in the North-Eastern region. In the parallel physician survey, 55.5% of respondents estimated that more than half of their patients self-medicated before consultation. Conclusion: In this platform-based sample, attitudes were the weakest domain, not knowledge, and 42.0% said their last antibiotic did not come on a doctor's recommendation. The findings may inform digital stewardship touchpoints, such as point-of-purchase guidance and prescription verification, in line with India's National Action Plan on Antimicrobial Resistance 2.0. As a cross-sectional survey of platform users, it cannot establish the relative contributions of knowledge, beliefs and access pathways to antibiotic use.
Sirima, S. B.; Richie, T. L.; Ouedraogo, A.; Soulama, B. I.; Zou, A. R.; Nebie, I.; KC, N.; Camargo, N.; Goswami, D.; Kabore, J. M. T.; Kirakoya, N.; Mbaiasra, R. K.; Ezinmegnon, S.; Badoum, E. S.; Ouedraogo, S. Y.; Henry, N. B.; Yaro, J. B.; Mabuka, T.; Murshedkar, T.; Abebe, Y.; Perez, D.; James, E. R.; Minkah, N.; Vaughan, A. M.; Laurens, M. B.; Sim, B. K. L.; Kappe, S. H. I.; Tiono, A. B.; Hoffman, S. L.
Show abstract
The World Health Organization has called for malaria vaccines with > 90% efficacy against Plasmodium falciparum (Pf) infection. The live, non-attenuated PfSPZ-CVac (chloroquine) vaccine provides the strongest protection against controlled human malaria infection (CHMI). Its 100% protective efficacy at 12 weeks against genetically distant Pf stems from a highly amplified immune stimulus. After inoculation, each invading sporozoite (SPZ) replicates up to 50,000 times within a hepatocyte. Over six days of development, these parasites express thousands of distinct proteins, presenting a vast and diverse array of antigens to the host immune system. The late liver stage parasites then rupture into the bloodstream, where they are killed by the co-administered drug, chloroquine. To engineer a Pf parasite that develops to the late liver stage like PfSPZ-CVac (chloroquine), but then arrests before transitioning to the blood stage, two genes required for transition from non-pathogenic liver to pathogenic blood stages were identified and deleted, creating late-liver stage arresting, replication-competent (LARC) PfSPZ. In a first-in-human, randomized, double-blind, placebo-controlled clinical trial, we assessed PfSPZ-LARC2 Vaccine in 75 malaria-exposed Burkinabe 1- to 48-year-olds. No vaccine-strain breakthrough blood-stage infections were detected; safety and tolerability profiles were similar in vaccinees and placebo recipients; and the highest immunogenicity was observed in the youngest recipients. Based on these findings, PfSPZ-LARC2 Vaccine has progressed to Phase 2 testing with the goal of rapidly advancing this genetically attenuated whole parasite vaccine to licensure and deployment.